RGNX compared with FATE: revenue, margins and what each company keeps, and the suppliers and customers both name

RGNXRegenxbio Inc.

Mkt capRevenueRevenue

FATEFate Therapeutics Inc

Mkt capRevenueRevenue

Compare

RGNXRegenxbio Inc.

FATEFate Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

RGNX: latest quarter not drawable. FATE: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only RGNX 17

ABBVAbbVie Global Enterprises Ltd. (AbbVie)customer

RAREUltragenyx Pharmaceuticalcustomer

GSKGlaxoSmithKline LLC (GSK)supplier

NVSNovartis Gene Therapies, Inc. (formerly AveXis, Inc.) (Novartis Gene Therapies)customer

13 more · RGNX chain ›

Shared 0

No shared counterparties.

Only FATE 8

—Baylor College of Medicineunlistedsupplier

—Dana Farber Cancer Instituteunlistedsupplier

—Memorial Sloan Kettering Cancer Centerunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—The Scripps Research Instituteunlistedsupplier

4 more · FATE chain ›

Price

rebased to 0%

RGNX, solidFATE, dashed

RGNXRegenxbio Inc.

7.20▼−2.83%· post 7.20

Mkt cap$475.3MRevenue$108MQ2 FY26Revenue$170MFY25

FATEFate Therapeutics Inc

2.08▼−4.16%· post 2.08

ClosedOct 30 '26

Mkt cap$249.2MRevenue$2MQ2 FY26Revenue$7MFY25

Compare

ClosedOct 30 '26

RGNXRegenxbio Inc.

FATEFate Therapeutics Inc

7.20▼−2.83%post 7.20

Price

2.08▼−4.16%post 2.08

$475.3M

Mkt cap

$249.2M

Q2 FY26$108M

Revenue

$2MQ2 FY26

FY25$170M

Revenue

$7MFY25

RGNX7.20▼−2.83%vsFATE2.08▼−4.16%ClosedOct 30 '26